UPDATE: Citi Upgrades Eli Lilly (LLY) to Buy
Tweet
Share
E-mailGet Alerts LLY Hot Sheet
Price: $1,160.00 +0.28%
Rating Summary:
30 Buy, 5 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 7 | New: 64
Rating Summary:
30 Buy, 5 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 7 | New: 64
Join SI Premium – FREE
(Updated - April 29, 2015 9:58 AM EDT)
Citi upgraded Eli Lilly (NYSE: LLY) from Neutral to Buy with a price target of $100. Analysts raised evacetrapib risk peak sales estimates from $1 billion to $3.8 billion. The change follows Merck (NYSE: MRK) IMPROVE-IT data that showed its Vytorin validates cardio benefit of lowering LDL cholesterol with a non-statin agent.
For an analyst ratings summary and ratings history on Eli Lilly click here. For more ratings news on Eli Lilly click here.
Shares of Eli Lilly closed at $71.18 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kepler Cheuvreux Upgrades Entain PLC (ENT:LN) (GMVHF) to Buy
- Raymond James Starts Community Trust Bancorp (CTBI) at Outperform
- Edison International (EIX) PT Lowered to $63 at UBS
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, Hot Upgrades, UpgradesRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
